Partridge Andrew John — SEC insider filings

SEC reporting owner CIK 1758838. 5 insider filings on record with FilingPulse; latest filed 2026-10-07.

Transaction summary — filings shown

Covers all 5 filings on record, filed 2021-02-10 to 2026-10-07. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
GRAIL, Inc. (GRAL)Chief Growth Officer2—2 legs · 9,364 sh · $1,243,599—
Turning Point Therapeutics, Inc. (TPTX)EVP & Chief Commercial Officer3—2 legs · 2,090 sh · $148,0104

Insider filings — Partridge Andrew John

FiledFormIssuerReported transactionsSource
2026-10-074GRAIL, Inc. (GRAL)Sale (S): 7,873 @ $146.39EDGAR
2026-06-054GRAIL, Inc. (GRAL)Sale (S): 1,491 @ $61.08EDGAR
2022-02-114Turning Point Therapeutics, Inc. (TPTX)Sale (S): 221 @ $36.30 · Grant/award (A): 16,283 @ $0 · Grant/award (A): 58,600 (derivative) @ $0EDGAR
2021-07-154Turning Point Therapeutics, Inc. (TPTX)Sale (S): 1,869 @ $74.90EDGAR
2021-02-104Turning Point Therapeutics, Inc. (TPTX)Grant/award (A): 2,136 @ $0 · Grant/award (A): 9,733 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-02-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1758838 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs